

02 June 2026

## Dermatology and Rheumatology New Patient Statistics

1. How many new patients were treated for any condition by the Trust's Dermatology Department in the latest 3-month period of January, February and March 2026 (or the latest 3 months available) with the treatments I have provided below?

If you are able to, could you please provide the split of new patients who received their treatment for Psoriasis.

Please can you define a "new patient" as a patient who is receiving any of the treatments listed below for the first time. If a patient received any of the below treatments in 2024 or previous years, they can be classed as a new patient for this period.

	Total Dermatology Department	Psoriasis
Adalimumab [Humira]	10	<5
Adalimumab [All Biosimilars]	196	160
Apremilast [Otezla]	0	0
Apremilast [Generic]	0	0
Etanercept [Enbrel]	0	0
Etanercept [All Biosimilars]	<5	<5
Infliximab [Remicade]	<5	<5
Infliximab [All Biosimilars]	0	0
Ustekinumab [Stelara]	<5	<5
Ustekinumab [All Biosimilars]	27	27
Bimekizumab [Bimzelx]	5	5
Brodalumab [Kyntheum]	<5	<5
Certolizumab [Cimzia]	5	5
Deucravacitinib [Sotyktu]	<5	<5
Dimethyl Fumarate [Skilarence]	0	0
Guselkumab [Tremfya]	55	55
Ixekizumab [Taltz]	24	24
Risankizumab [Skyrizi]	44	43
Secukinumab [Cosentyx]	32	28
Spesolimab [Spevigo]	0	0
Tildrakizumab [Illumetri]	<5	<5

02 June 2026

2. How many new patients were treated for any condition by the Trust's Rheumatology Department in the latest 3-month period of January, February and March 2026 (or the latest 3 months available) with the treatments I have provided below?

If you are able to, could you please provide the split of new patients who received their treatment for Axial Spondyloarthritis (axSpA), Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA).

	Total Rheumatology Department	Axial Spondyloarthritis (axSpA)	Rheumatoid Arthritis (RA)	Psoriatic Arthritis (PsA)
Abatacept [Orencia]	<5		<5	0
Adalimumab [Humira]	27	0	13	14
Adalimumab [All Biosimilars]	0	0	0	0
Apremilast [Otezla]	0			0
Apremilast [Generic]	10			7
Baricitinib [Olumiant]	<5		<5	
Bimekizumab [Bimzelx]	<5	0		<5
Certolizumab [Cimzia]	<5	0	<5	<5
Etanercept [Enbrel]	0	0	0	0
Etanercept [All Biosimilars]	14	<5	5	7
Filgotinib [Jyseleca]	0		0	
Golimumab [Simponi]	0	0	0	0
Golimumab [All Biosimilars]	<5	<5	0	0
Guselkumab [Tremfya]	<5		<5	0
Infliximab [Remicade]	0	0	0	0
Infliximab [All Biosimilars]	<5	<5	<5	0
Ixekizumab [Taltz]	0	0		0
Risankizumab [Skyrizi]	<5			<5
Rituximab [MabThera]	0		0	
Rituximab [Biosimilars]	0		0	

02 June 2026

Sarilumab [Kevzara]	0		0	
Secukinumab [Cosentyx]	5	5		0
Tocilizumab [RoActemra]	0		0	
Tocilizumab [Biosimilars]	5		5	
Tofacitinib [Xeljanz]	0	0	0	0
Upadacitinib [Rinvoq]	<5	0	0	<5
Ustekinumab [Stelara]	<5			<5
Ustekinumab Biosimilar	0			0

\* Where numbers are low we have put <5 rather than state the actual figure. To ensure that patient remain non identifiable. Disclosure of this information would breach the first data protection principle, which relates to the fair and lawful processing of personal data. Therefore, we have concluded that this information is exempt from disclosure under Section 40(2) of the Freedom of Information Act - Personal Information relating to a third party.